Company news
Axsome Therapeutics, Inc. news in 2026
Axsome Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
November 19, 2026
Axsome Therapeutics to Participate in Upcoming Investor Conferences
November 3, 2026
Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
November 2, 2026
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
October 7, 2026
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
September 21, 2026
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
September 17, 2026
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
August 31, 2026
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 10, 2026
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
July 15, 2026
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
July 14, 2026
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
July 7, 2026
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
June 26, 2026
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
June 18, 2026
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
June 15, 2026
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
June 3, 2026
Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
June 3, 2026
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
June 1, 2026
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
May 26, 2026
Axsome Therapeutics Recognizes Mental Health Month
May 7, 2026
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 4, 2026
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
May 1, 2026
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
April 30, 2026
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4
April 7, 2026
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
March 31, 2026
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
February 23, 2026
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 22, 2026
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 17, 2026
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
February 17, 2026
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
January 26, 2026
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
January 14, 2026
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
January 11, 2026
Calls in 2026
- Axsome Therapeutics (NASDAQ:AXSM) Q3 2026 Earnings Call
Nov 2, 2026
Transcript - Axsome Therapeutics (NASDAQ:AXSM) Q2 2026 Earnings Call
Aug 10, 2026
Transcript - Axsome Therapeutics (NASDAQ:AXSM) Q1 2026 Earnings Call
May 4, 2026
Transcript - Axsome Therapeutics (NASDAQ:AXSM) Q4 2025 Earnings Call
Feb 23, 2026
Transcript
Decks in 2026
- Investor Presentation (November 2026)
Investor deck · 50 slides · November 2026
- Q2 2026 Earnings Presentation
Earnings · 46 slides · Aug 10, 2026
- Q1 2026 Earnings Presentation
Earnings · 49 slides · May 4, 2026
- Investor Presentation (May 2026)
Investor deck · 26 slides · May 1, 2026
- Q4 2025 Earnings Presentation
Earnings · 47 slides · Feb 23, 2026